All data are based on the daily closing price as of September 16, 2025
h

Hanmi Pharm. Co.

128940.KO
231.06 USD
15.56
+7.22%

Overview

Last close
231.06 usd
Market cap
2.93B usd
52 week high
257.29 usd
52 week low
146.58 usd
Target price
263.34 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
2.7767
Price/Book Value
3.3595
Enterprise Value
2.93B usd
EV/Revenue
2.7584
EV/EBITDA
15.3416

Key financials

Revenue TTM
1.06B usd
Gross Profit TTM
581.05M usd
EBITDA TTM
211.75M usd
Earnings per Share
N/A usd
Dividend
0.91 usd
Total assets
1.45B usd
Net debt
259.10M usd

About

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.
  • Symbol
    128940.KO
  • Exchange
    KO
  • Isin
    KR7128940004
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Jae-Hyun Park
  • Headquarter
    Hwaseong-si
  • Web site
    https://www.hanmipharm.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top